Lv410
418 积分 2025-09-23 加入
A generalizable pathology foundation model using a unified knowledge distillation pretraining framework
28天前
已完结
Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy
28天前
已完结
A Phase II, Randomized, open-label study to evaluate low-dose Pembrolizumab plus Chemotherapy vs Chemotherapy as Neoadjuvant Therapy for localized Triple Negative Breast Cancer (TNBC). [PLANeT Trial - Pembrolizumab Low Dose in Addition to NACT in TNBC]
28天前
已关闭
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
28天前
已完结
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study
28天前
已关闭
Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): a randomised, controlled, phase 2–3 trial
28天前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
28天前
已完结
Predicting neoadjuvant breast cancer therapy response using BRIDGE from tumor transcriptomics and histopathology
30天前
已关闭
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
30天前
已完结
Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial
30天前
已完结
皖公网安备34019202002308
